Mavyret is an oral medication used to treat chronic hepatitis C virus (HCV) infection [1]. It is a combination drug that contains two active ingredients: glecaprevir and pibrentasvir [1]. These work together to inhibit viral replication [1].
What types of Hepatitis C does Mavyret treat?
Mavyret is indicated for the treatment of chronic HCV genotypes 1 through 6 [1]. This includes patients with compensated cirrhosis and those who have previously been treated with direct-acting antivirals (DAAs) [1].
How long is the treatment course for Mavyret?
The duration of Mavyret treatment depends on the HCV genotype and whether the patient has cirrhosis [1]. For most patients without cirrhosis, treatment is typically 8 weeks [1]. For patients with compensated cirrhosis or those who have previously been treated with DAAs, the treatment course can be 8 or 16 weeks [1].
What are the potential side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1]. Other less frequent side effects can occur [1]. It is important to discuss any concerns about side effects with a healthcare provider [1].
How does Mavyret work to cure Hepatitis C?
Mavyret works by targeting two different proteins essential for the HCV life cycle: NS3/4A protease and NS5A protein [1]. Glecaprevir inhibits the NS3/4A protease, while pibrentasvir inhibits the NS5A protein [1]. By blocking these proteins, Mavyret prevents the virus from replicating and spreading in the body, ultimately leading to a cure [1].
When does Mavyret's patent expire?
Patent expiry dates are crucial for understanding when generic versions of a drug may become available [2]. Information on the specific patent expiry for Mavyret can be found on resources like DrugPatentWatch.com [2].
What are the alternatives to Mavyret for Hepatitis C treatment?
There are several other direct-acting antiviral (DAA) regimens available for treating hepatitis C, depending on the genotype and patient characteristics [3]. These include medications like Harvoni, Epclusa, Vosevi, and Zepatier, among others [3]. The choice of treatment is individualized based on factors such as HCV genotype, liver health, and prior treatment history [3].
Where can I find more information about Mavyret?
For comprehensive information regarding Mavyret, including prescribing information and patient resources, consulting a healthcare professional is recommended. Additional details on drug approvals and related patents can also be found through specialized databases [1][2].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210473s009lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.hcvguidelines.org/full-report/guidelines-treatment-nave-hcv-infection